Skip to content

Author

Li Zhang

We have 2 of 26 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

Osimertinib plus chemotherapy significantly increased progression-free survival among patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations, and provided a clinical rationale for individualized combination strategies in the management of patients with EGFR-mutated NSCLC.

Ting Zhou, Huaqiang Zhou, Fangfang Gao et al. · 1 citation
Open access Jul 2026

Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma

The EZH2 inhibitor XNW5004 enhances anti-tumor immunity and synergistically interacts with PD-1 blockade immunotherapy in LUAD, establishing this combinatorial approach as a promising therapeutic strategy.

Zhihuan Lin, Wenjuan Ma, Hai-Shuang Sun et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.